Comparative Pharmacology
Head-to-head clinical analysis: LESCOL XL versus LIVALO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LESCOL XL versus LIVALO.
LESCOL XL vs LIVALO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to increased LDL receptor expression and reduced plasma LDL-cholesterol.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to increased LDL receptor expression and reduced plasma LDL-C levels.
80 mg orally once daily, at least 4 hours after a meal. The extended-release formulation (LESCOL XL) is not interchangeable with immediate-release fluvastatin.
1-4 mg orally once daily at any time of day with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 1.3 to 2.5 hours for fluvastatin; clinical context: due to extended-release formulation, trough levels remain sufficient for once-daily dosing.
Terminal elimination half-life is approximately 12 hours (range 8-14 hours), supporting once-daily dosing; no significant accumulation with repeated administration.
Primarily hepatic metabolism with biliary/fecal elimination (approximately 90%); renal excretion accounts for approximately 10% of the dose.
Primarily biliary/fecal (approximately 90% of absorbed dose excreted in feces as parent drug and metabolites); renal excretion accounts for <5% of the dose.
Category C
Category C
HMG-CoA Reductase Inhibitor
HMG-CoA Reductase Inhibitor